Alaunos Therapeutics gets Nasdaq delisting notice over $2.5M equity rule; plans hearing

Alaunos Therapeutics, Inc.

Nasdaq staff notified Alaunos on Oct. 5, 2026 that its securities are subject to delisting for failing Listing Rule 5550(b)(1), the $2,500,000 minimum stockholders' equity requirement.
Company first received non-compliance notice on April 9, 2026 and submitted a timely plan to regain compliance; that plan was not accepted.
Alaunos plans to timely request a hearing before the Nasdaq Hearings Panel, which stays suspension or delisting at least until the hearing and any extension expires.
Company is working with a financial advisor to evaluate strategic alternatives and potential transactions to regain listing compliance; no assurance any deal will be signed or completed.
Common stock trades on Nasdaq Capital Market under symbol TCRT; signed by CEO Holger Weis, dated October 9, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.